MARKET

TVTX

TVTX

Travere Therapeutics Inc
NASDAQ
59.99
-1.58
-2.57%
After Hours: 59.99 0 0.00% 19:30 09/29 EDT
OPEN
61.04
PREV CLOSE
61.57
HIGH
61.87
LOW
59.33
VOLUME
1.57M
TURNOVER
--
52 WEEK HIGH
68.73
52 WEEK LOW
22.06
MARKET CAP
5.65B
P/E (TTM)
-121.0941
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TVTX last week (0921-0925)?
Weekly Report · 1d ago
Travere Therapeutics Is Maintained at Buy by Guggenheim
Dow Jones · 5d ago
Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $89
Benzinga · 5d ago
Travere Therapeutics price target raised to $89 from $75 at Guggenheim
TipRanks · 5d ago
Guggenheim Sticks to Its Buy Rating for Travere Therapeutics (TVTX)
TipRanks · 5d ago
Analysts Offer Insights on Healthcare Companies: Royalty Pharma (RPRX), Travere Therapeutics (TVTX) and Veeva Systems (VEEV)
TipRanks · 5d ago
Travere Therapeutics receives notice of allowance for FILSPARI patent
TipRanks · 6d ago
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
Barchart · 6d ago
More
About TVTX
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

Webull offers Travere Therapeutics Inc stock information, including NASDAQ: TVTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TVTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TVTX stock methods without spending real money on the virtual paper trading platform.